Interleukin-6 is present in early stages of plaque formation and is restricted to the brains of Alzheimer's disease patients
The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
Interleukin-6 (IL-6) immunoreactivity has previously been shown in plaques in Alzheimer's disease (AD) and elevated IL-6 concentrations have been measured biochemically in brains of AD patients. In this study, we investigated the appearance of IL-6 immunoreactivity in AD plaques according to the stage of plaque formation. Using the Bielschowsky silver-staining method, we were able to differentiate between four types of plaques described earlier: diffuse, primitive, classic and compact. While diffuse plaques represent the early stage of plaque formation, primitive and classic plaques are thought to represent later stages of plaque development. We investigated serial sections of paraffin-embedded cortices of ten clinically diagnosed and histopathologically confirmed AD patients and ten patients with no clinical history of dementia. We found plaques in the brains of both nondemented and demented persons using the silver staining method or immunohistochemistry with antibodies against the amyloid precursor protein. In the group of clinically nondemented persons, diffuse plaques were the predominant plaque type, whereas primitive plaques formed the larger portion of lesions in the group of AD brains. IL-6 could not be detected in plaques of patients without dementia. Many IL-6-positive plaques were found in six of the AD brains and to a smaller extent in the other four AD cases. In the six cases with a large number of IL-6-positive plaques, IL-6 was found in a significantly higher…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Interleukin-6, a typical SASP mediator, is upregulated in the aged brain and in AD [96,97,98] and its overexpression has been shown to drive neurodegeneration in vivo [99].”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [97]
In the citing paper
“Most notably, IL-6, IL-1β, TGF-β and TNF-α levels have been reported to be elevated in AD brain tissue [96,97,212,213,214]”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [97]
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
Baumann, H., & Gauldie, J. (1994) · Immunology Today · doi:10.1016/0167-5699(94)90137-6 · Cited by 2,899
Diagnosis of Alzheimer's Disease
Khachaturian, Z. S. (1985) · Archives of Neurology · doi:10.1001/archneur.1985.04060100083029 · Cited by 2,499
Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity
DeKosky, S. T., & Scheff, S. W. (1990) · Annals of Neurology · doi:10.1002/ana.410270502 · Cited by 2,376
Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6.
Campbell, I. L., Abraham, C. R., Masliah, E., Kemper, P., Inglis, J. D., Oldstone, M. B., & Mucke, L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.21.10061 · Cited by 1,006
Abraham, C. R., Selkoe, D. J., & Potter, H. (1988) · Cell · doi:10.1016/0092-8674(88)90462-x · Cited by 900
Roberts, G. W., Gentleman, S. M., Lynch, A., Murray, L., Landon, M., & Graham, D. I. (1994) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.57.4.419 · Cited by 569
Excitatory amino acids and Alzheimer's disease
Greenamyre, J. T., & Young, A. B. (1989) · Neurobiology of Aging · doi:10.1016/0197-4580(89)90143-7 · Cited by 484
Research works printed but not linked: 4
- Ikeda S, Glenner GG (1989) Morphology and distribution of plaque and related deposits in the brains of Alzheimer's disease and control cases. Lab Invest 60:113?122
- Jellinger K, Bancher C, Fischer P, Lassmann H (1992) Quantitative histopathologic validation of senile dementia of the Alzheimer type. Eur J Gerontol 3:146?156
- Mirra SS, Hart MN, Terry RD (1993) Making the diagnosis of Alzheimer's disease. Arch Pathol Lab Med 117:132?144
- Wisniewski HM, Terry RD (1973) Reexamination of the pathogenesis of the senile plaque. Prog Neuropathol 2:1?26
Cited by
Items 201–214 of 214
Pathological Changes in the Elderly Human Brain
Mann, D. M. A. (1997) · Springer eBooks · doi:10.1007/978-1-4615-6001-2_2
Inflammatory pathology in neurodegenerative dementias
Niedermayer, G. (2014)
The Physiopathological Crossroads of Aging
Lasierra-Cirujeda, J., Coronel, P., Pascual-Salcedo, M. J. A., Gimeno, M., Salcedo, M. M. A. P., Lasierra-Ibañez, A., & AZA, C. L. (2019) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2019.76007
“Also, there are significantly elevated concentrations of these cytokines in the cerebrospinal fluid of neurodegenerative processes in AD and Parkinson’s disease [201] intervening in the transformation of diffuse plaques [202] or pre-amyloid deposits [203], very extended in the brain, in AD neuritic plaques [204], requ…”
BackgroundCytokine Regulation in Alzheimer’s Disease
Mrak, R. E. (2003) · Neurobiological foundation of aberrant behaviors · doi:10.1007/978-1-4615-0323-1_17 · Cited by 1
Poynter, M. E., & Daynes, R. A. (2011) · De Gruyter eBooks · doi:10.1515/9783110811162.65
Mackenzie, I. R. (2001) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-8350-4_11
Bucci, L., Ostan, R., Capri, M., Salvioli, S., Cevenini, E., Celani, L., Monti, D., & Franceschi, C. (2009) · Springer eBooks · doi:10.1007/978-1-4020-9063-9_45 · Cited by 2
(2007) · Steinkopff eBooks · doi:10.1007/978-3-7985-1787-5_7
The Fundamental Role of Neuroinflammation at the Beginning and Progression of Alzheimer’s Disease
Sawikr, Y. (2022) · Scientific Journal for Faculty of Science-Sirte University · doi:10.37375/sjfssu.v2i2.91
Petals of Potency: Navigating the Bioactive Landscape of Coffee Flowers
Das, M., Lalsangi, S. B., Santra, S., Khamaru, D., Singh, M. P., & Banerjee, R. (2025) · Springer eBooks · doi:10.1007/978-981-96-3663-1_12 · Cited by 1
Fu, X., Huang, J., Liu, Y., Li, H., & Zhang, Y. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1797302
“IL-6 plays a role in the early formation of amyloid plaques in the brains of individuals with AD (Huell et al., 1995) and has been associated with tau phosphorylation (Quintanilla et al., 2004).”
Risco-Acevedo, D., Subirós, N., Camacho, H., Ramírez-Sánchez, J., Rodríguez-Virulich, Y., Etchegoyen-Amoros, A., Hernández-Estrada, W., Wong-Guerra, M., Montano-Peguero, Y., Estrada-Olivares, T., et al. (2026) · Neurotoxicity Research · doi:10.1007/s12640-026-00807-0
“Beyond these effects, IL-6 is involved in early stages of amyloid plaque formation and has been associated with tau phosphorylation, synaptic loss, and learning deficits in murine models (Heyser et al. 1997; Huell et al. 1995; Quintanilla et al. 2004).”
Wood, P. L. (2026) · Life · doi:10.3390/life16101684
“For example, while significant elevation of cortical IL-6 levels has been monitored in LOAD [75,76], Il-6 levels are not elevated in NDAN subjects [75].”
Inflammatory proteins in the CNS-relation to Alzheimers disease
Lindberg, C. (2005) · Figshare
Metadata
- Authors
- Huell, M., Strauss, S., Volk, B., Berger, M., & Bauer, J.
- Affiliations
- University of Freiburg (DE)
- ORCID
- Strauss, Sylvia
- Venue
- Acta Neuropathologica
- Published
- 1995
- Volume
- 89
- Issue
- 6
- Pages
- 544-551
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- OpenAlex
- W2001259634
- Cited by
- 214
- References
- 53
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 8 · 2023: 9 · 2022: 8 · 2021: 7 · 2020: 6 · 2019: 3 · 2018: 3 · 2017: 2 · 2016: 4 · 2015: 5 · 2014: 8 · 2013: 2 · 2012: 4
- FWCI
- 8.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Acta Neuropathologica (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bundesministerium für Forschung und Technologie
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- interleukin-6, Alzheimer's disease, amyloid plaques, plaque type, diffuse plaques, amyloid precursor protein, cerebral cortex, dementia, neuroinflammation
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Brain, Brain Chemistry, Humans, Immunohistochemistry, Middle Aged, Interleukin-6, Silver Staining
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.